Scynexis (SCYX) Allergic Medicines Case

The case has been dismissed, typically without any further action.

D. New Jersey

Court

2:23-cv-22082

Case number

03/31/2023

Class period Start

09/22/2023

Class period End

01/06/2024

Lead Plaintiff motion deadline

Scynexis recalled its medicines due to potential allergic reactions.
On September 26, 2023, the truth came out, leading to a 11% $SCYX fall.
On September 25, 2023, Scynexis recalled its antifungal medication ibrexafungerp and temporarily halted clinical trials due to contamination risk. 

This was caused by an unwanted substance found during production that could lead to allergic reactions and hypersensitivity.

This news caused $SCYX fall by 11% and $9.29M loss of market cap, damaging shareholders.

Given all this information, investors have reason to suspect that Scynexis misled about the effectiveness and safety of its drug.

Case Type

US Securities Class Action

Case Status

Dismissed

Alleged Offence

Mismanagement,

Misleading Statements,

Negligence,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

09/26/2023

Filing date

11/07/2023

Lead Plaintiff Deadline

01/06/2024

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.